Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stefano Sganga
Observed name:
S. Sganga
Institutions:
Università Cattolica del Sacro Cuore,
Agostino Gemelli University Polyclinic,
Istituti di Ricovero e Cura a Carattere Scientifico
Observed institutions:
Università Cattolica del Sacro Cuore,
University of Rome Tor Vergata,
Agostino Gemelli University Polyclinic,
Policlinico Tor Vergata,
Istituti di Ricovero e Cura a Carattere Scientifico
ORCID:
0000-0002-1991-377X
Observed ORCID:
0000-0002-1991-377X
OpenAlex ID:
A5054296168
Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review
2022
·
Giovanni Maria Iannantuono
, Silvia Riondino
, et al.
·
International Journal of Molecular Sciences
·
34
PDF
NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
2022
·
Giovanni Maria Iannantuono
, Silvia Riondino
, et al.
·
Journal of Personalized Medicine
·
25
PDF
The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer
2022
·
Giovanni Maria Iannantuono
, Francesco Torino
, et al.
·
International Journal of Molecular Sciences
·
25
PDF
Current landscape of T-cell engagers in early-phase clinical development in solid cancers
2025
·
Andrea Spinazzola
, Giovanni Maria Iannantuono
, et al.
·
Frontiers in Immunology
·
18
PDF
Antibody–Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives
2023
·
Stefano Sganga
, Silvia Riondino
, et al.
·
Journal of Personalized Medicine
·
16
PDF
Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009–2023)
2025
·
Giovanni Maria Iannantuono
, Charalampos S. Floudas
, et al.
·
European Journal of Cancer
·
10
PDF
Impact of ECOG performance status 2 participants on outcomes of pivotal cancer clinical trials: a meta-analysis and meta-regression
2026
·
G.M. Iannantuono
, T. Giovagnoli
, et al.
·
ESMO Open
·
6
Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review
2025
·
Roberto Rosenfeld
, Stefano Sganga
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
5
PDF
Artificial intelligence in oncology publishing: a systematic review and policy analysis of high-impact journals
2026
·
Raffaele Giusti
, Marco Filetti
, et al.
·
Frontiers in Oncology
·
3
PDF
Temporal patterns and factors associated with early termination in phase 1 clinical trials for solid tumors
2026
·
Giovanni Maria Iannantuono
, Stefano Sganga
, et al.
·
JNCI Journal of the National Cancer Institute
·
3
Correction: Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review
2025
·
Roberto Rosenfeld
, Stefano Sganga
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
1
PDF
1633P Why do cancer clinical trials (CT) discontinue prematurely in the era of COVID-19?
2021
·
G.M. Iannantuono
, F. Torino
, et al.
·
Annals of Oncology
·
1
PDF
Early termination of clinical trials enrolling patients with breast cancer: Reasons, determinants, and temporal patterns
2026
·
Giovanni Maria Iannantuono
, Gennaro Daniele
, et al.
·
The Breast
PDF
2322P Editorial oversight of AI in high-impact oncology journals: A cross-sectional policy analysis
2025
·
M. Filetti
, P. Lombardi
, et al.
·
Annals of Oncology
3190eP Prognostic value of unplanned hospital attendances in early phase cancer trial participants
2025
·
P. Lombardi
, M. Filetti
, et al.
·
Annals of Oncology
1585P Performance status restrictions in clinical trials leading to US food and drug administration (FDA) drug approval: A cross-sectional study of a decade (2014-2023)
2024
·
G.M. Iannantuono
, M. Filetti
, et al.
·
Annals of Oncology
PDF
84P Lack of diversity in clinical trials leading to Food and Drug Administration (FDA) approvals for gynaecological cancers
2024
·
E. Giudice
, S. Sganga
, et al.
·
ESMO Open
PDF
Review of: "Advancements in the Detection and Treatment of Rare ALK Fusion Mutations in Hepatocellular Carcinoma: A Case Report and Literature Review"
2024
·
Stefano Sganga
·
Qeios
PDF
Review of: "Personalized (tailored) treatment with antiresorptive drugs (bisphosphonates, denosumab) in patients with bone metastases from solid tumors – A “Pico” document by Rete Oncologica Piemonte-Valle D’Aosta Bone Metastatic Disease Study Group"
2023
·
Stefano Sganga
·
Qeios
PDF
Show more works
View as search
Works count:
19
Citation count:
147
H-index:
6
I10-index:
6
Year
Topic
Type